Shanghai, China - On November 21-27, 2022, the 12^th Shanghai Genitourinary Oncology International Symposium & Chinese Society of Clinical Oncology Prostate Cancer Committee Summit & 2022 Annual Meeting of Shanghai Anti-Cancer Association-Genitourinary Cancer Committee ("Shanghai Genitourinary Oncology International Symposium") was held. Shanghai MicroPort MedBot (Group) Co., Ltd. ("MicroPort^® MedBot^®"), as the representative of domestic laparoscopic robots, presented the latest clinical application progress of Toumai^® Laparoscopic Surgical Robot to the experts, and received praise from the audience for its leading technology and numerous clinical breakthroughs.

Shanghai Genitourinary Oncology International Symposium has been held for 12 years since 2011, and has grown into a comprehensive forum that brings together top experts, leading scientists, young and middle-aged scholars, innovative research teams and translational medicine teams in the field of genitourinary oncology worldwide. Shanghai Genitourinary Oncology International Symposium, renowned for its high quality, high level platform and content, has firmly established its position as the top international conference in the field of male genitourinary tumor, and has evolved as the "authoritative academic exchange meeting, new platform for international cooperation, innovative research vane and new drug and technology booth" in this field.

The conference was co-organized by CSCO-PC, Shanghai Anti-Cancer Association-Genitourinary Cancer Committee, Beijing Health Promotion Association and Beijing Sci-Tech Innovation Medical Development Foundation, and hosted by Fudan University Shanghai Cancer Center. A series of academic activities were held in the form of "Academic Week", such as master class on male genitourinary tumor surgery, multidisciplinary comprehensive treatment of difficult cases, interpretation of prostate cancer treatment guidelines, forum for young and middle-aged scholars on the frontier of genitourinary tumor, and competition on excellent innovative genitourinary tumor surgical procedures. Shanghai Genitourinary Oncology International Symposium, the grand finale of which was held on 25-26, invited experts from home and abroad to gather in Shanghai to discuss the major annual advances in the field of male genitourinary tumor. In addition to the popular events that were well received in the previous years, the conference released blockbuster news - "Chinese Expert Consensus on Prostate Cancer Puncture”, the annual offering - "Top 100 Institutions on Genitourinary Tumor in China in 2022", the innovation engine - "New Drug and Technology Cooperation Model", and the annual review - "International Genitourinary Tumor Progress in 2022". Full of surprises, the conference was widely recognized by the industry experts and it welcomed more than 400,000 views online.

Academician Xu Zhang, Director Designate of CUA, Prof. Jian Huang, Director of CUA, Professor Nianzeng Xing, President of CUDA, Prof. Changling Li, Director of CACA-GU, Prof. Xin Yao, Director Designate of CACA-GU, Prof. Zhisong He, Vice Director of CSCO-PC, Vice Director of CPCC, Prof. Benkang Shi, Vice Director of CSCO-PC, Vice Director of CPCC, and Prof. Jun Qi, Prof. Xiaodong Xie, Prof. Fangjian Zhou and Prof. Qiang Wei, Vice Director of CSCO-PC attended the conference. Besides, a number of well-known domestic experts were present, including Prof. Dingwei Ye, Director of Shanghai Institute of Genitourinary Oncology, Chairman of Shanghai Anti-Cancer Association-Genitourinary Cancer Committee, Director of CSCO-PC, Vice Director of CUA Oncology Group, Prof. Junhua Zheng, Vice Director of CUA, Prof. Wei Xue, Vice Director of Urology Branch of Shanghai Medical Doctor Association, Prof. Linhui Wang, Chairman of the Urinary Surgery Doctor Branch of Shanghai Medical Doctor Association, and fellow members of the Standing Committee and experts from all over China.

Prof. Dingwei Ye, the chairman of the conference, said in his speech that since its inception, the conference has achieved remarkable achievements with the purpose of "learning from each other and seeking common ground while reserving differences". International multi-center cooperation and regional collaboration should be enhanced. Based on the characteristics of the Chinese population, targeted treatment guidelines and expert consensus on male genitourinary cancers shall be established. Guided by the principle of "Intelligent Manufacturing in China 2025", independent innovative drugs and new technologies shall be promoted to the world to fully implement the great initiative of "Healthy China".

Many experts expressed that experts and scholars in the field of genitourinary oncology from home and abroad gathered in Shanghai to share the academic feast, and that the forum has been fruitful during the past eleven years. The achievements are particularly noteworthy, providing a valuable platform for urological colleagues across the country to share exquisite surgical skills, the latest treatment concepts and technical achievements. Such efforts effectively promoted the development of clinical and scientific research in the field of genitourinary oncology in China.

During the conference, Prof. Xu Gao from the Urology of The First Affiliated Hospital of Naval Medical University (Changhai Hospital) shared a wonderful lecture with the theme of "Experience Sharing on the Application of Domestic Laparoscopic Surgical Robot in Genitourinary Tumors" in the module of "Practice Guidelines of Three Major Genitourinary Tumors". The excellent performance and surgical operation of the domestic robot were shared with the attending fellow experts in the field of genitourinary oncology.

Professor Xu Gao said that it is well known that robotic surgical console is another leap in the history of surgical development from traditional laparotomy to ordinary laparoscopic surgery and then to robotic-assisted laparoscopic surgery, which is of great significance to the reachability of surgery and the improvement of treatment efficacy in actuality. Currently, the U.S. has a much higher number of laparoscopic robots per million people than China. Although the domestic market for robotic surgery has not yet been fully opened, robotic surgery is destined to be a future trend in China's medical industry with the support and encouragement of relevant national policies. Last year was the "first year" of domestic laparoscopic robots, in which MicroPort^® MedBot^®, currently as the only surgical robot company in the world that covers the five "Gold Races" of endoscope, orthopedics, vascular intervention, natural orifice and percutaneous puncture, has brought more prides and opportunities to the Chinese people.

As a clinical expert of the Toumai^® Laparoscopic Surgical Robot, Prof. Xu Gao participated in the design and implementation of the whole process, including product R&D, registration, and clinical study. According to Prof. Xu Gao, in the clinical trials to evaluate the effectiveness and safety of robot-assisted urological surgery, higher standards were put forward for the Toumai^® Laparoscopic Surgical Robot; through a randomized controlled clinical trial with international robots in a close clinical design, it finally completed 102 registered clinical cases, becoming the first four-armed domestic laparoscopic robot to complete a clinical trial in urology. It was verified that there was no statistically significant difference between Toumai^® and the control group in terms of the integrity of tumor resection, the effectiveness of bleeding control and the protection of normal tissue function, which fully demonstrated that the Toumai^® Laparoscopic Surgical Robot has reached the international leading level. Prof. Xu Gao then explained in detail the advantages of Toumai^® with the surgical videos of kidney tumor resection and radical prostatectomy - accurate and flexible, client-server remote operation, abundant instruments, and endoscopic autonomous control, which all lay a solid foundation for the future clinical application of Toumai^®.

Prof. Xu Gao introduced that to make high-quality medical resources more accessible, MicroPort^® MedBot^® keeps exploring boundaries and looking for breakthroughs. In June 2022, from Kizilsu Kirghiz Autonomous Prefecture, Xinjiang to Nanjing, Jiangsu, Toumai^® successfully completed the world's longest distance tele-operated robotic surgery via 5G networks, which will help solve the bottleneck of surgical technology in more hospitals in remote and less developed areas and enhance the feasibility of realizing to carry out difficult and complex surgeries. Patients can also receive remote surgical treatment from top experts "without leaving their hometowns", and there is no need to seek medical treatment in other places in this scenario. Toumai^® continues to challenge difficult procedures. On September 28, 2022, Toumai^® successfully helped complete the first radical treatment for left renal cancer with renal vein cancer assisted with a domestic surgical robot, which was operated by the team of Director Lingwu Chen of Department of Urology from The First Affiliated Hospital of Sun Yat-sen University. On November 5, 2022, Prof. Shuo Wang, Director of the Urology Department of the First Affiliated Hospital of Zhejiang University School of Medicine, successfully performed a live streaming of the radical prostatic cancer surgery completed through the extraperitoneal approach with the help of Toumai^®, which was also the first surgical live streaming performed by Toumai^® at the 2022 Robotics and Minimally Invasive Urology Surgery Forum; on the same day, a robot-assisted radical nephrectomy via retroperitoneal approach was completed. These cases fully prove the safety and reliability of Toumai^®.

As the first and only domestic four-armed laparoscopic robot approved for marketing by NMPA, Toumai^® has accomplished several first breakthroughs in complex surgical procedures in China, and has completed more than 400 robot-assisted clinical validation surgeries in urology, general surgery, gynecology and thoracic surgery in 13 provinces and 22 hospitals across China. In the future, MicroPort^® MedBot^® will continue to devote to technological innovation, application and upgrading, provide more efficient, comprehensive robotic intelligent surgical total solutions to the society, realizing the original intention of "Make Surgery Easier, Safer and Less Invasive".